Arrowhead Pharmaceuticals (ARWR) Revenue (2010 - 2026)

Arrowhead Pharmaceuticals' Revenue history runs 17 years deep, the most recent figure standing at $73.7 million for Q1 2026.

• Quarterly Revenue fell 86.41% year-over-year to $73.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $622.0 million (up 14.09% YoY) and the FY2025 annual result came in at $829.4 million, up 23258.15% from the prior year.
• Revenue was $73.7 million for Q1 2026 at Arrowhead Pharmaceuticals, down from $264.0 million in the prior quarter.
• Across five years, Revenue topped out at $542.7 million in Q1 2025 and bottomed at $2.5 million in Q4 2024.
• A 5-year average of $116.2 million and a median of $47.5 million in 2022 frame the typical range for Revenue.
• Annual changes were most pronounced in 2023 — Revenue slumped 94.32% — and 2025, when it jumped 10461.32%.
• Arrowhead Pharmaceuticals' Revenue stood at $62.5 million in 2022, then slumped by 94.32% to $3.6 million in 2023, then dropped by 29.6% to $2.5 million in 2024, then soared by 10461.32% to $264.0 million in 2025, then tumbled by 72.07% to $73.7 million in 2026.
• Business Quant data shows ARWR's Revenue at $73.7 million in Q1 2026, $264.0 million in Q4 2025, and $256.5 million in Q3 2025.